Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Kevin Buczkowski

Podiatrist, Foot & Ankle Surgery Brockton, MA Doctor of Podiatric Medicine

NPI 1891316477 CMS profile 8803258

680 Centre St, Brockton, MA 02302

Open in the dashboard

General payments

$4,495

52 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Buczkowski of Brockton, MA is reported in the CMS Open Payments database as having received $4,495 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $624 11
2024 General $253 4
2023 General $155 4
2022 General $1,930 22
2021 General $1,506 9
2020 General $27 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Buczkowski
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Kevin Buczkowski were reported at $624. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Kevin Buczkowski Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $27 $191 $62–$691 $114
2021 $1,506 $329 $104–$1,341 $132
2022 $1,930 $419 $125–$1,611 $149
2023 $155 $377 $128–$1,164 $160
2024 $253 $394 $134–$1,168 $164
2025 $624 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Kairos Surgical Inc $2,434 4 payments
  2. Integra LifeSciences Corporation $595 13 payments
  3. Smith+Nephew, Inc. $356 18 payments
  4. Kerecis Limited $310 4 payments
  5. Arthrex, Inc. $201 3 payments
  6. Carbofix Orthopedics Inc $138 1 payment
  7. LifeNet Health $127 1 payment
  8. Avita Medical Americas, LLC $125 2 payments
  9. Trilliant Surgical LLC. $90 1 payment
  10. Bioventus LLC $67 3 payments
  11. Other $53 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Education $2,400 2 payments
  2. Food and Beverage $1,934 49 payments
  3. Travel and Lodging $161 1 payment
Products named General payments · program years 2020–2025
  1. INTEGRA DERMAL REGENERATION TEMPLATE $595 13 payments
  2. PRIMATRIX $595 13 payments
  3. Integra Recon-Skin And Wound $467 11 payments
  4. Integra Recon-Skin And Wound $467 11 payments
  5. Integra Recon-Skin And Wound $467 11 payments
  6. Kerecis SurgiClose Wound Care $224 3 payments
  7. Kerecis SurgiClose Wound Care $224 3 payments
  8. Kerecis SurgiClose Wound Care $224 3 payments
  9. Kerecis GraftGuide $224 3 payments
  10. Kerecis SurgiClose Wound Care $224 3 payments
  11. Other $2,094 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

169

Median for Podiatry: 160

Drug cost

$1,665

Median for Podiatry: $2,368

Branded share of claims

6.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 20 $459
Diclofenac Sodium Generic 15 $280
Terbinafine Hcl Generic 22 $207
Methylprednisolone Generic 23 $169
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $142
Oxycodone Hcl Generic 29 $128
Meloxicam Generic 26 $103
Doxycycline Hyclate Generic 11 $95
Cephalexin Generic 12 $82

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$61,552

Of which drugs: $27

Medicare patients

403

Average age 73

Services billed

898

198 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 43%
Depression 31%
Chronic kidney disease 28%
Ischemic heart disease 26%
COPD 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 22 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record